Peter Kramer

Dr. Peter Kramer

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2018 in Congenital Heart Disease
Verified
Journal Article
Closed access
PDF file
LKLaura S. Kverneland
Laura S. Kverneland
PKPeter Kramer
Peter Kramer
SOStanislav Ovroutski
Stanislav Ovroutski
Almost fifty years after its first clinical application, the modified Fontan operation is among the most frequently performed procedures in congenital heart disease surgery in children today. The objective of this review is to systematically summarize the international evolution of outcomes in regard to morbidity and mortality of patients with Fontan palliation. All studies published over the past five decades with more than 100 Fontan patients included were screened. In eligible studies, information concerning preoperative patients' characteristics, Fontan modifications employed, early mortality, long-term survival and frequency of relevant complications was extracted. Ultimately, thirty-one studies published by the largest surgical centers with an overall number of 9390 patients were included in this review. The extracardiac total cavopulmonary anastomosis is the most frequently used Fontan modification. Hemodynamic data demonstrate a rigorous overall adherence to suggested Fontan selection criteria. The analysis showed a clear trend toward improved early and long-term survival over the time period covered. Although inconsistently reported, severe complications such as arrhythmias, thromboembolic events and protein-losing enteropathy as well as reoperations and reinterventions were frequent. In conclusion, patients palliated for complex univentricular heart malformations nowadays benefit from the experience and technical developments of the past decades and have a significantly improved long-term prognosis. However, important issues concerning postoperative long-term morbidity and mortality are still unsolved and clear intrinsic limitations of the Fontan circulation are becoming evident as the population of Fontan patients ages.

13 February 2013 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
SNSofie Nelissen
Sofie Nelissen
ELEvi Lemmens
Evi Lemmens
NGNathalie Geurts
Nathalie Geurts
PKPeter Kramer
Peter Kramer
MMMarcus Maurer
Marcus Maurer
SHSven Hendrix
Sven Hendrix

27 November 2012 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
SHSven Hendrix
Sven Hendrix
PKPeter Kramer
Peter Kramer
DPDebora Pehl
Debora Pehl
KWKatharina Warnke
Katharina Warnke
FBFrancesco Boato
Francesco Boato
MMMarcus Maurer
Marcus Maurer
Mast cells (MCs) are found abundantly in the brain and the meninges and play a complex role in neuroinflammatory diseases, such as stroke and multiple sclerosis. Here, we show that MC‐deficient Kit W /Kit Wv mice display increased neurodegeneration in the lesion area after brain trauma. Furthermore, MC‐deficient mice display significantly more brain inflammation, namely an increased presence of macrophages/microglia, as well as dramatically increased T‐cell infiltration at days 4 and 14 after injury, combined with increased astrogliosis at day 14 following injury. The number of proliferating Ki67 + macrophages/microglia and astrocytes around the lesion area is more than doubled in these MC‐deficient mice. In parallel, MC‐deficient Kit W‐sh / W‐sh mice display increased presence of macrophages/microglia at day 4, and persistent astrogliosis at day 4 and 14 after brain trauma. Further analysis of mice deficient in one of the most relevant MC proteases, i.e. , mouse mast cell protease 4 (mMCP‐4), revealed that astrogliosis and T‐cell infiltration are significantly increased in mMCP‐4‐knockout mice. Finally, treatment with an inhibitor of mMCP‐4 significantly increased macrophage/microglia numbers and astrogliosis. These data suggest that MCs exert protective functions after trauma, at least in part via mMCP‐4, by suppressing exacerbated inflammation via their proteases.—Hendrix, S., Kramer, P., Pehl, D., Warnke, K., Boato, F., Nelissen, S., Lemmens, E., Pejler, G., Metz, M., Siebenhaar, F., Maurer, M. Mast cells protect from post‐traumatic brain inflammation by the mast cell‐specific chymase mouse mast cell protease‐4 . FASEB J. 27, 920–929 (2013). www.fasebj.org

1 January 2018 in Resuscitation
Verified
Journal Article
Closed access
PKPeter Kramer
Peter Kramer
OMOliver Miera
Oliver Miera
FBFelix Berger
Felix Berger
KSKatharina Schmitt
Katharina Schmitt

1 December 2021 in International Journal of Cardiology
Verified
Journal Article
Closed access
HSHannes Sallmon
Hannes Sallmon
SOStanislav Ovroutski
Stanislav Ovroutski
ASAnastasia Schleiger
Anastasia Schleiger
JPJoachim Photiadis
Joachim Photiadis
SWSven C. Weber
Sven C. Weber
PKPeter Kramer
Peter Kramer

10 March 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PKPeter Kramer
Peter Kramer
ASAnastasia Schleiger
Anastasia Schleiger
MSMarie Schafstedde
Marie Schafstedde
FDFriederike Danne
Friederike Danne
JNJohannes Nordmeyer
Johannes Nordmeyer
SOStanislav Ovroutski
Stanislav Ovroutski
Objectives: Despite the outstanding success of the Fontan operation, it is a palliative procedure and a substantial number of patients experience late failure of the Fontan circulation. Clinical presentation and hemodynamic phenotypes of Fontan failure are considerably variable. While various parameters have been identified as risk factors for late Fontan failure, a feasible score to classify Fontan failure and possibly allow timely risk stratification is lacking. Here, we explored the possibility of developing a score based on hemodynamic, clinical and laboratory parameters to classify Fontan failure and mortality.Methods: We performed a retrospective study in our cohort of adult Fontan patients from two institutions [n = 198, median follow-up after Fontan 20.3 (IQR 15.6–24.3) years], identifying those patients with clinical Fontan failure (n = 52, 26.3%). Various hemodynamic, echocardiographic, laboratory and clinical data were recorded and differences between patients with and without Fontan failure were analyzed. We composed a Fontan Failure Score containing 15 parameters associated with Fontan failure and/or mortality and assessed its accuracy to discriminate between patients with and without late Fontan failure as well as late mortality and survival.Results: Late failure occurred at a median of 18.2 (IQR 9.1–21.1) years after Fontan completion. Mortality associated with Fontan failure was substantial (25/52, 48.1%) with freedom of death/transplantation/take-down of 64% at 5 years and 36% at 10 years after onset of Fontan failure, respectively. Patients with Fontan failure had a significantly higher median Fontan Failure Score compared to non-failing Fontan patients [8 points (IQR 5–10) vs. 2 points (IQR 1-5), p < 0.001]. The score accurately classifies Fontan failure as well as mortality as assessed with receiver operating characteristic analysis. Area under the curve of the Fontan Failure Score was 0.963 (95% CI 0.921; 0.985, p < 0.001) to discriminate failure and 0.916 (95% CI 0.873; 0.959, p < 0.001) to classify mortality.Conclusion: We have developed an uncomplex yet remarkably accurate score to classify Fontan failure and late mortality in adult Fontan patients. Prospective validation and most likely refinement and calibration of the score in larger and preferably multi-institutional cohorts is required to assess its potential to predict the risk of Fontan failure and late mortality.